The biotechnology company Amgen was founded in 1980 as AMGen. With approximately 20,000 employees, Amgen is one of the world's largest biotechnology companies with annual sales of approximately $ 24 billion in 2018.
SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) [ X ] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 1997 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 0-12477 AMGEN INC. (Exact name of registrant as specified in its charter) Delaware 95-3540776 - ------------------------------- ----------------------------- (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 1840 DeHavilland Drive, Thousand Oaks, California 91320-1789 - --------------------------------------------------------------------- (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (805) 447-1000 Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes X No As of June 30, 1997, the registrant had 265,136,353 shares of Common Stock, $.0001 par value, outstanding.
AMGEN INC. INDEX Page No. PART I FINANCIAL INFORMATION Item 1.Financial Statements .......................3 Condensed Consolidated Statements of Operations - three and six months ended June 30, 1997 and 1996 ....................4 Condensed Consolidated Balance Sheets - June 30, 1997 and December 31, 1996 .............5 Condensed Consolidated Statements of Cash Flows - six months ended June 30, 1997 and 1996 ..................6-7 Notes to Condensed Consolidated Financial Statements ...................................8-16 Item 2.Management's Discussion and Analysis of Financial Condition and Results of Operations .............................17-23 PART II OTHER INFORMATION Item 1.Legal Proceedings .........................23 Item 4.Submission of Matters to a Vote of of Security Holders .......................27 Item 6.Exhibits and Reports on Form 8-K ..........28 Signatures........................................29 Index to Exhibits.................................30 2
PART I - FINANCIAL INFORMATION Item 1. Financial Statements The information in this report for the three and six months ended June 30, 1997 and 1996 is unaudited but includes all adjustments (consisting only of normal recurring accruals) which Amgen Inc. ("Amgen" or the "Company") considers necessary for a fair presentation of the results of operations for those periods. The condensed consolidated financial statements should be read in conjunction with the Company's financial statements and the notes thereto contained in the Company's Annual Report on Form 10-K for the year ended December 31, 1996. Interim results are not necessarily indicative of results for the full fiscal year. 3
AMGEN INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In millions, except per share data) (Unaudited) Three Months Ended Six Months Ended June 30, June 30, 1997 1996 1997 1996 -------- -------- -------- -------- Revenues: Product sales ............... $566.7 $518.9 $1,102.7 $ 995.8 Corporate partner revenues .. 40.0 42.0 67.4 63.8 Royalty income .............. 13.8 10.5 25.9 19.7 ------ ------ -------- -------- Total revenues ............ 620.5 571.4 1,196.0 1,079.3 ------ ------ -------- -------- Operating expenses: Cost of Sales ............... 76.8 68.3 148.8 135.2 Research and development .... 145.4 123.6 293.1 254.2 Marketing and selling ....... 81.8 78.5 149.9 146.1 General and administrative .. 43.7 37.8 88.1 77.0 Loss of affiliates, net ..... 12.1 14.9 20.6 28.2 ------ ------ -------- -------- Total operating expenses... 359.8 323.1 700.5 640.7 ------ ------ -------- -------- Operating income ............. 260.7 248.3 495.5 438.6 ------ ------ -------- -------- Other income (expense): Interest and other income ... 18.0 12.2 33.9 31.2 Interest expense, net ....... (0.4) (1.7) (0.7) (4.0) ------ ------ -------- -------- Total other income (expense) ................ 17.6 10.5 33.2 27.2 ------ ------ -------- -------- Income before income taxes ... 278.3 258.8 528.7 465.8 Provision for income taxes ... 77.8 80.1 147.9 143.5 ------ ------ -------- -------- Net income ................... $200.5 $178.7 $ 380.8 $ 322.3 ====== ====== ======== ======== Earnings per share: Primary ..................... $0.72 $0.64 $1.37 $1.14 Fully diluted ............... $0.72 $0.64 $1.37 $1.14 Shares used in calculation of earnings per share: Primary ..................... 277.5 280.9 277.8 282.2 Fully diluted ............... 277.5 280.9 277.8 282.2 See accompanying notes. 4
AMGEN INC. CONDENSED CONSOLIDATED BALANCE SHEETS (In millions, except per share data) (Unaudited) June 30, December 31, 1997 1996 --------- ----------- ASSETS Current assets: Cash and cash equivalents ............... $ 331.0 $ 169.3 Marketable securities ................... 894.0 907.7 Trade receivables, net .................. 228.8 225.4 Inventories ............................. 105.6 97.4 Other current assets .................... 86.2 102.8 -------- -------- Total current assets................. 1,645.6 1,502.6 Property, plant and equipment at cost, net 1,045.4 910.5 Investments in affiliated companies....... 111.7 109.6 Other assets.............................. 240.6 242.9 -------- -------- $3,043.3 $2,765.6 ======== ======== LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable ........................ $ 82.6 $ 75.0 Accrued liabilities ..................... 440.5 449.7 Current portion of long-term debt ....... 65.0 118.2 -------- -------- Total current liabilities............ 588.1 642.9 Long-term debt............................ 134.0 59.0 Put warrants.............................. 51.6 157.4 Commitments and contingencies Stockholders' equity: Common stock, and additional paid-in capital; $.0001 par value; 750 shares authorized; outstanding - 265.1 shares in 1997 and 264.7 shares in 1996..... 1,114.5 1,026.9 Retained earnings ....................... 1,155.1 879.4 -------- -------- Total stockholders' equity........... 2,269.6 1,906.3 -------- -------- $3,043.3 $2,765.6 ======== ======== See accompanying notes. 5
AMGEN INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In millions) (Unaudited) Six Months Ended June 30, 1997 1996 ------ ------ Cash flows from operating activities: Net income ................................. $380.8 $322.3 Depreciation and amortization .............. 65.1 54.9 Loss of affiliates, net .................... 20.6 28.2 Cash provided by (used in): Trade receivables, net .................... (3.4) 0.5 Inventories ............................... (8.2) (3.0) Other current assets ...................... 16.6 8.2 Accounts payable .......................... 7.6 (1.4) Accrued liabilities ....................... (9.2) (14.4) ------ ------ Net cash provided by operating activities 469.9 395.3 ------ ------ Cash flows from investing activities: Purchases of property, plant and equipment . (195.0) (92.7) Proceeds from maturities of marketable securities ............................... 184.3 129.9 Proceeds from sales of marketable securities 312.4 449.6 Purchases of marketable securities ......... (483.0) (393.7) Decrease (increase) in investments in affiliated companies ..................... 3.2 (5.5) Increase in other assets ................... (2.7) (65.7) ------ ------ Net cash (used in) provided by investing activities ............................ (180.8) 21.9 ------ ------ See accompanying notes. (Continued on next page) 6
AMGEN INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Continued) (In millions) (Unaudited) Six Months Ended June 30, 1997 1996 ------ ------- Cash flows from financing activities: Repayment of long-term debt ................ $(78.2) $ - Proceeds from issuance of long-term debt ... 100.0 - Decrease in commercial paper ............... - (69.7) Net proceeds from issuance of common stock upon the exercise of stock options . 59.0 45.7 Tax benefits related to stock options ...... 28.6 15.8 Repurchases of common stock ................ (210.9) (234.8) Other ...................................... (25.9) (26.7) ------ ------ Net cash used in financing activities .... (127.4) (269.7) ------ ------ Increase in cash and cash equivalents ....... 161.7 147.5 Cash and cash equivalents at beginning of period .................................... 169.3 66.7 ------ ------ Cash and cash equivalents at end of period .. $331.0 $214.2 ====== ====== See accompanying notes. 7
AMGEN INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS June 30, 1997 1. Summary of significant accounting policies Business Amgen Inc. ("Amgen" or the "Company") is a global biotechnology company that discovers, develops, manufactures and markets human therapeutics based on advances in cellular and molecular biology. Principles of consolidation The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries as well as affiliated companies for which the Company has a controlling financial interest and exercises control over their operations ("majority controlled affiliates"). All material intercompany transactions and balances have been eliminated in consolidation. Investments in affiliated companies which are 50% or less owned and where the Company exercises significant influence over operations are accounted for using the equity method. All other equity investments are accounted for under the cost method. The caption "Loss of affiliates, net" includes Amgen's equity in the operating results of affiliated companies and the minority interest others hold in the operating results of Amgen's majority controlled affiliates. Inventories Inventories are stated at the lower of cost or market. Cost is determined in a manner which approximates the first-in, first-out (FIFO) method. Inventories are shown net of applicable reserves and allowances. Inventories consist of the following (in millions): June 30, December 31, 1997 1996 ------ ------- Raw materials ...... $ 14.8 $15.9 Work in process .... 49.8 56.2 Finished goods ..... 41.0 25.3 ------ ----- $105.6 $97.4 ====== ===== Product sales Product sales consist of two products, EPOGEN(R) (Epoetin alfa) and NEUPOGEN(R) (Filgrastim). 8
Quarterly NEUPOGEN(R) sales volume in the United States is influenced by a number of factors including underlying demand and wholesaler inventory management practices. Wholesaler inventory reductions tend to reduce domestic NEUPOGEN(R) sales in the first quarter each year. In addition, the discretionary aspects of some cancer chemotherapy administration has had a slight seasonal effect on NEUPOGEN(R) sales. The Company has the exclusive right to sell Epoetin alfa for dialysis, diagnostics and all non-human uses in the United States. The Company sells Epoetin alfa under the brand name EPOGEN(R). Amgen has granted to Ortho Pharmaceutical Corporation, a subsidiary of Johnson & Johnson ("Johnson & Johnson"), a license relating to Epoetin alfa for sales in the United States for all human uses except dialysis and diagnostics. Pursuant to this license, Amgen does not recognize product sales it makes into the exclusive market of Johnson & Johnson and does recognize the product sales made by Johnson & Johnson into Amgen's exclusive market. These sales amounts, and adjustments thereto, are derived from Company shipments and from third-party data on shipments to end users and their usage (see Note 4, "Contingencies - Johnson & Johnson arbitrations"). Foreign currency transactions The Company has a program to manage foreign currency risk. As part of this program, it has purchased foreign currency option and forward contracts to hedge against possible reductions in values of certain anticipated foreign currency cash flows generally over the next 12 months, primarily resulting from its sales in Europe. At June 30, 1997, the Company had option and forward contracts to exchange foreign currencies for U.S. dollars of $24.8 million and $22.8 million, respectively, all having maturities of seven months or less. The option contracts, which have only nominal intrinsic value at the time of purchase, are designated and effective as hedges of anticipated foreign currency transactions for financial reporting purposes, and accordingly, the net gains on such contracts are deferred and will be recognized in the same period as the hedged transactions. The forward contracts do not qualify as hedges for financial reporting purposes, and accordingly, are marked-to-market. Net gains on option contracts (including option contracts for hedged transactions whose occurrence are no longer probable) and changes in market values of forward contracts are reflected in interest and other income. The deferred premiums on option contracts and fair values of forward contracts are included in other current assets. The Company has additional foreign currency forward contracts to hedge exposures to foreign currency fluctuations of certain receivables and payables denominated in foreign currencies. At June 30, 1997, the Company had forward contracts to exchange foreign currencies, primarily Swiss francs, for U.S. dollars of $54.6 million, all having maturities of six months or less. These contracts are designated and effective as hedges, and accordingly, gains and losses on these forward contracts are recognized in the same period the offsetting gains and losses of hedged assets and liabilities are realized and recognized. The fair values of the 9
forward contracts are included in the corresponding captions of the hedged assets and liabilities. Gains and losses on forward contracts, to the extent they differ in amount from the hedged receivables and payables, are included in interest and other income. Income taxes Income taxes are accounted for in accordance with Statement of Financial Accounting Standards ("SFAS") No. 109 (Note 3). Stock option and purchase plans The Company's stock options and purchase plans are accounted for under Accounting Principles Board Opinion No. 25, "Accounting for Stock Issued to Employees". Earnings per share Primary and fully diluted earnings per share are based upon the weighted average number of common shares and dilutive common stock equivalents during the period in which they were outstanding. Common stock equivalents are outstanding options under the Company's stock option plans which are included in the earnings per share computation under the treasury stock method. Put warrants on the Company's common stock may also be dilutive and included in earnings per share under the reverse treasury stock method. In February 1997, SFAS No. 128, "Earnings Per Share" was issued and is required to be adopted on December 31, 1997. At that time, the Company will be required to change the method currently used to compute earnings per share and to restate all prior periods. Under the new requirements, primary and fully diluted earnings per share will be replaced with basic and diluted earnings per share. Basic earnings per share excludes the dilutive effect of stock options and will therefore be higher than primary earnings per share. Basic earnings per share for the three and six months ended June 30, 1997 were $.76 and $1.44, respectively. Basic earnings per share for the three and six months ended June 30, 1996 were $.67 and $1.21, respectively. Diluted earnings per share under the new standard is expected to be essentially the same as primary earnings per share amounts calculated under principles currently used. Use of estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results may differ from those estimates. Basis of presentation The financial information for the three and six months ended June 30, 1997 and 1996 is unaudited but includes all adjustments (consisting only of normal recurring accruals) which the Company 10
considers necessary for a fair presentation of the results of operations for these periods. Interim results are not necessarily indicative of results for the full fiscal year. 2. Debt During the first quarter of 1997, the Company paid off $78.2 million of maturing debt consisting of $28.2 million of promissory notes and $50 million of debt securities. Long-term debt consists of the following (in millions): June 30, December 31, 1997 1996 -------- -------- Promissory notes .......... $ 40.0 $ 68.2 Debt securities ........... 159.0 109.0 ------ ------ 199.0 177.2 Less current portion ...... (65.0) (118.2) ------ ------ $134.0 $ 59.0 ====== ====== The Company has registered $213 million of unsecured debt securities of which $159 million were outstanding and none were available for issuance at June 30, 1997. At June 30, 1997, $59 million of these debt securities then outstanding bear interest at fixed rates averaging 5.8% and mature in approximately one to six years. In April 1997, the Company issued the remaining $100 million of debt securities under its shelf registration which bear interest at a fixed rate of 8.1% and mature on April 1, 2097. These securities may be redeemed in whole or in part at the Company's option at any time for a redemption price equal to the greater of the principal amount to be redeemed or the sum of the present values of the principal and remaining interest payments discounted at a determined rate plus, in each case, accrued interest. These securities place limitations on liens and sale/leaseback transactions. As of June 30, 1997, $150 million was available under the Company's line of credit for borrowing and to support the Company's commercial paper program. No borrowings on this line of credit were outstanding at June 30, 1997. 3. Income taxes 11
The provision for income taxes consists of the following (in millions): Three Months Ended Six Months Ended June 30, June 30, 1997 1996 1997 1996 ------ ------ ------ ------ Federal(including U.S. possessions)... $72.3 $72.8 $137.4 $130.1 State ................ 5.5 7.3 10.5 13.4 ----- ----- ------ ------ $77.8 $80.1 $147.9 $143.5 ===== ===== ====== ====== The decrease in the effective tax rate in the current year is the result of a favorable ruling received in the third quarter of 1996 from the Puerto Rican government with respect to tollgate taxes applicable to earnings in Puerto Rico. 4. Contingencies Johnson & Johnson arbitrations In September 1985, the Company granted Johnson & Johnson a license relating to certain patented technology and know-how of the Company to sell a genetically engineered form of recombinant human erythropoietin, called Epoetin alfa, throughout the United States for all human uses except dialysis and diagnostics. Johnson & Johnson sells Epoetin alfa under the brand name PROCRIT(R). A number of disputes have arisen between Amgen and Johnson & Johnson as to their respective rights and obligations under the various agreements between them, including the agreement granting the license (the "License Agreement"). These disputes have been the subject of arbitration proceedings before Judicial Arbitration and Mediation Services, Inc. in Chicago, Illinois commencing in January 1989. A dispute that has not yet been resolved and is the subject of the current arbitration proceeding relates to the audit methodology currently employed by the Company for Epoetin alfa sales. The Company and Johnson & Johnson are required to compensate each other for Epoetin alfa sales which either party makes into the other party's exclusive market. The Company has established and is employing an audit methodology to assign the proceeds of sales of EPOGEN(R) and PROCRIT in Amgen's and Johnson & Johnson's respective exclusive markets. Based upon this audit methodology, the Company is seeking payment of approximately $12.6 million (excluding interest) from Johnson & Johnson for the period 1991 through 1994. Johnson & Johnson has disputed this methodology and is proposing an alternative methodology for adoption by the arbitrator pursuant to which it is seeking payment of approximately $423 million (including interest through December 1996) for the period 1989 through 1994. If as a result of the arbitration proceeding, a methodology different from that currently employed by the Company is instituted to assign the proceeds of sales between the parties, it may yield results that are 12
different from the results of the audit methodology currently employed by the Company. As a result of the arbitration, it is possible that the Company would recognize a different level of EPOGEN(R) sales than is currently being recognized. As a result of the arbitration, the Company may be required to pay additional compensation to Johnson & Johnson for sales during prior periods, or Johnson & Johnson may be required to pay compensation to the Company for such prior period sales. While it is impossible to predict accurately or determine the outcome of these proceedings, based primarily upon the merits of its claims and based upon certain liabilities established due to the inherent uncertainty of any arbitrated result, the Company believes that the outcome of these proceedings will not have a material adverse effect on its financial statements. A trial commenced in March 1996, regarding the audit methodologies and compensation for sales by Johnson & Johnson into Amgen's exclusive market and sales by Amgen into Johnson & Johnson's exclusive market. In December 1996, testimony in the arbitration ended. Final argument before the arbitrator on the parties' respective audit methodologies and claims occurred on May 19, 1997, whereafter the matter was fully briefed and submitted to the arbitrator for decision. The Company has filed a demand in the arbitration to terminate Johnson & Johnson's rights under the License Agreement and to recover damages for breach of the License Agreement. Johnson & Johnson disputes Arbitrator McGarr's jurisdiction to decide the Company's demand. A hearing before Arbitrator McGarr on the Company's demand will be scheduled following his adjudication of the audit methodologies for Epoetin alfa sales. On October 2, 1995, Johnson & Johnson filed a demand for a separate arbitration proceeding against the Company before the American Arbitration Association ("AAA") in Chicago, Illinois. Johnson & Johnson alleges in this demand that the Company has breached the License Agreement. The demand also includes allegations of various antitrust violations. In this demand, Johnson & Johnson seeks an injunction, declaratory relief, unspecified compensatory damages, punitive damages and costs. On October 27, 1995, the Company filed a complaint in the Circuit Court of Cook County, Illinois seeking an order compelling Johnson & Johnson to arbitrate the Company's claim for termination before Arbitrator McGarr as well as all related counterclaims asserted in Johnson & Johnson's October 2, 1995 AAA arbitration demand. The Company is unable to predict at this time the outcome of the demand for termination or when it will be resolved. The Company has filed a motion to stay the AAA arbitration pending the outcome of the existing arbitration proceedings before Judicial Arbitration and Mediation Services, Inc. discussed above. The Company has also filed an answer and counterclaim denying that AAA has jurisdiction to hear or decide the claims stated in the demand, denying the allegations in the demand and counter claiming for certain unpaid invoices. On June 5, 1997, Ortho Biotech, Inc., a Johnson & Johnson affiliate, filed a demand for arbitration against Kirin-Amgen, Inc. ("Kirin-Amgen"), before the American Arbitration Association ("AAA"). 13
The demand alleges that Amgen's novel erythropoiesis stimulating protein ("NESP") is covered by a license granted by Kirin-Amgen to Ortho Pharmaceutical Corporation in 1985 for the development, manufacture and sale of Epoetin alfa in certain territories outside the United States, Japan and China. In 1996 Kirin-Amgen acquired exclusive worldwide rights in NESP from Amgen. Kirin-Amgen, in turn, transferred certain rights in NESP to Kirin and certain rights to Amgen. Ortho Biotech alleges that Ortho Pharmaceutical's 1985 license agreement with Kirin-Amgen effectively grants Ortho Biotech the same right to develop, manufacture and sell NESP as Kirin-Amgen previously granted to Ortho Pharmaceutical in 1985 for the development, manufacture and sale of Epoetin alfa. On June 20, 1997 Kirin-Amgen initiated suit in the Circuit Court of Cook County, Illinois seeking a judicial determination of Ortho Biotech's standing to seek arbitration of claims under Kirin-Amgen's 1985 license agreement with Ortho Pharmaceutical. At the same time, Kirin-Amgen filed a motion with AAA to dismiss or stay the arbitration pending judicial resolution of Ortho Biotech's standing to arbitrate claims under Kirin-Amgen's license agreement with Ortho Pharmaceutical. Synergen ANTRIL(TM) litigation Lawsuits have been filed against the Company's wholly-owned subsidiary, Amgen Boulder Inc. (formerly Synergen, Inc.), alleging misrepresentations in connection with Synergen's research and development of ANTRIL(TM) for the treatment of sepsis. One suit, filed by a limited partner of the partnership with which Amgen Boulder Inc. is affiliated, has been certified as a class action. That suit seeks rescission of certain payments made by the limited partners to the partnership (or unspecified damages not less than $52 million) and treble damages based on a variety of allegations relating to state and federal law claims. The plaintiffs in that suit also have filed a second amended complaint alleging violations of federal securities laws. In August and September 1996, the parties filed cross-motions for summary judgement. The Court heard argument on November 1, 1996. Since then, the parties' representatives have reached a tentative settlement agreement which is subject to final approval by the Court and the approval of the limited partners of the partnership. Under its terms, the plaintiffs, who include present limited partners of the partnership, will receive $14.5 million in exchange for the transfer of ownership of their units; the suit will be dismissed with prejudice and the parties will exchange mutual releases. In a separate matter, on June 13, 1997, the parties in the matter Susquehanna Investment Group, et al. v. Amgen Boulder, Inc., et al., agreed to a settlement in that matter in which Amgen Boulder, Inc. agreed to pay $1 million in exchange for dismissal of the suit. On July 23, 1997, the lawsuit was dismissed with prejudice. FoxMeyer Health Corporation On January 10, 1997, FoxMeyer Health Corporation, now known as Avatex Corporation ("Avatex"), filed suit (the "FoxMeyer Lawsuit") in the District Court of Dallas County, Dallas, Texas, alleging that defendant McKesson Corporation ("McKesson") defrauded Avatex, misused 14
confidential information received from Avatex about subsidiaries of Avatex (FoxMeyer Corporation and FoxMeyer Drug Corporation, collectively the "FoxMeyer Subsidiaries"), and attempted to monopolize the market for pharmaceutical and health care product distribution by attempting to injure or destroy the FoxMeyer Subsidiaries. The Company is named as one of twelve "Manufacturer Defendants" alleged to have conspired with McKesson Corporation in doing, among other things, the above and (i) inducing Avatex to refrain from seeking other suitable purchasers for the FoxMeyer Subsidiaries and (ii) causing Avatex to believe that McKesson was serious about purchasing Avatex's assets at fair value, when, in fact, McKesson was not. The Manufacturer Defendants and McKesson are also alleged to have intentionally and tortiously interfered with a number of business expectancies and opportunities. The complaint seeks from the Manufacturer Defendants and McKesson compensatory damages of at least $400 million and punitive damages in an unspecified amount, as well as Avatex's costs and attorney's fees. On January 31, 1997, the Company filed an answer denying Avatex's allegations. On February 4, 1997, a Notice of Removal was filed in the Federal District Court for Dallas, Texas (the "District Court"), which was referred by the District Court to the Federal Bankruptcy Court in Dallas, Texas (the "Texas Bankruptcy Court"). Subsequently, on February 7, 1997, a Motion to Transfer Venue was filed in the Texas Bankruptcy Court requesting that this matter be transferred to the Federal Bankruptcy Court in Delaware (the "Delaware Bankruptcy Court"), where the FoxMeyer Subsidiaries' Chapter 7 bankruptcy action is pending. The Company is a creditor in such bankruptcy proceeding. Avatex had moved to remand the case to state court. On March 18, 1997, the Manufacturer Defendants filed in the Delaware Bankruptcy Court a Motion to Intervene in the creditors' committee (the "Chapter 11 Committee") action that asserted that the Delaware Bankruptcy Court should enjoin the FoxMeyer Lawsuit. Also on March 18, 1997, the Delaware Bankruptcy Court converted the FoxMeyer Subsidiaries' Chapter 11 bankruptcy action to a liquidation proceeding under Chapter 7. The order converting the FoxMeyer Subsidiaries' bankruptcy to a Chapter 7 proceeding also stayed all adversary proceedings and other proceedings filed in the bankruptcy until a permanent trustee was elected. As of August 1, 1997, although the issues are fully briefed, no ruling has been made by the Dallas Bankruptcy Court with respect to either the Motion to Transfer Venue to the Delaware Bankruptcy Court or the Avatex Motion to Remand to state court. The trustee has moved to intervene as plaintiff in the Dallas Bankruptcy Court action, has filed a memorandum supporting transfer and has also filed a memorandum opposing remand or abstention. McKesson has intervened in the Delaware Bankruptcy Court action to enjoin the Avatex lawsuit and has moved for partial summary judgment in that proceeding, asserting that Avatex is not the owner of the alleged causes of action. The Manufacturer Defendants have also intervened in that Delaware Bankruptcy Court action and have joined in McKesson's summary judgment motion. The trustee has substituted for the Chapter 11 Committee as the plaintiff in that action and has also filed its motion for partial summary judgment also asserting that Avatex does not own the causes of action. Avatex has moved to file its response to McKesson's motion for partial summary judgment under seal by reason of various deposition materials 15
originally taken pursuant to a confidentiality order which materials are being utilized in connection with the partial summary judgment. McKesson has objected. Avatex has filed its answer and affirmative defenses to the McKesson complaint for injunction. To date, no discovery has occurred in either the Dallas Bankruptcy Court adversary proceedings or the Delaware Bankruptcy Court adversary proceeding for injunction. There are no pleadings yet on file by either the trustee, McKesson or the Manufacturer Defendants concerning the issue whether McKesson owns the alleged causes of action rather than the Chapter 7 trustee. While it is not possible to predict accurately or determine the eventual outcome of the above described legal matters or various other legal proceedings (including patent disputes) involving Amgen, the Company believes that the outcome of these proceedings will not have a material adverse effect on its financial statements. 5. Stockholders' equity During the six months ended June 30, 1997, the Company repurchased 3.5 million shares of its common stock at a total cost of $210.9 million under its common stock repurchase program. The Board of Directors has authorized the Company to repurchase up to $450 million of shares during 1997. Stock repurchased under the program is retired. 16
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations Liquidity and Capital Resources Cash provided by operating activities has been and is expected to continue to be the Company's primary source of funds. During the six months ended June 30, 1997, operations provided $469.9 million of cash compared with $395.3 million during the same period last year. The Company had cash, cash equivalents and marketable securities of $1,225 million at June 30, 1997, compared with $1,077 million at December 31, 1996. Capital expenditures totaled $195 million for the six months ended June 30, 1997, compared with $92.7 million for the same period a year ago. The Company anticipates spending approximately $350 million to $400 million on capital projects and equipment to expand the Company's global operations in 1997. Thereafter over the next few years, capital expenditures are expected to average approximately $350 million per year. The Company receives cash from the exercise of employee stock options. During the six months ended June 30, 1997, stock options and their related tax benefits provided $87.6 million of cash compared with $61.5 million for the same period last year. Proceeds from the exercise of stock options and their related tax benefits will vary from period to period based upon, among other factors, fluctuations in the market value of the Company's stock relative to the exercise price of such options. The Company has a stock repurchase program to offset the dilutive effect of its employee stock option and stock purchase plans. During the six months ended June 30, 1997, the Company purchased 3.5 million shares of its common stock at a cost of $210.9 million compared with 4 million shares purchased at a cost of $234.8 million during the same period last year. The Company expects to repurchase up to $450 million of its stock under the program in 1997. 17
During the six months ended June 30, 1997, the Company repaid $50 million of debt securities that had been issued under the Company's former shelf registration statement (the "Shelf"). At June 30, 1997, an aggregate of $159 million was issued and outstanding under the Shelf, with no additional issuances remaining under the Shelf. Of these debt securities outstanding under the Shelf, $59 million bear interest at fixed rates averaging 5.8% and mature in approximately one to six years. In April 1997, the Company issued $100 million of debt securities under the Shelf which bear interest at a fixed rate of 8.1% and mature on April 1, 2097. These debt securities were issued to refinance a portion of debt that has matured or will mature in 1997 (see Note 2 to the Condensed Consolidated Financial Statements). The Company also repaid $28.2 million of promissory notes during the six months ended June 30, 1997. The Company also has sources of debt financing in order to provide for financial flexibility and increased liquidity. The Company has a commercial paper program which provides for short-term borrowings up to an aggregate face amount of $200 million. The Company also has a $150 million revolving line of credit for borrowings and to support the commercial paper program. As of June 30, 1997, no amounts were outstanding under either source. The primary objectives for the Company's investment portfolio are liquidity and safety of principal. Investments are made to achieve the highest rate of return to the Company, consistent with these two objectives. The Company's investment policy limits investments to certain types of instruments issued by institutions with investment grade credit ratings and places restrictions on maturities and concentration by type and issuer. The Company invests its excess cash in securities with varying maturities to meet projected cash needs. The Company believes that existing funds, cash generated from operations and existing sources of debt financing are adequate to satisfy its working capital and capital expenditure requirements for the foreseeable future, as well as to support its stock repurchase program. However, the Company may raise additional capital from time to time to take advantage of favorable conditions in the markets or in connection with the Company's corporate development activities. Results of Operations Product sales Product sales increased 9% and 11% for the three and six months ended June 30, 1997, respectively, compared with the same periods last year. NEUPOGEN(R) (Filgrastim) Worldwide NEUPOGEN(R) sales were $271.8 million and $516.2 million for the three and six months ended June 30, 1997, respectively. These amounts represent increases of $17.1 million and 18
$28.7 million or 7% and 6%, respectively, over the same periods last year. These increases are primarily due to demand growth in domestic and, to a lesser extent, international markets. Unfavorable foreign currency effects and tight European government budget issues reduced growth in European Union ("EU") sales. In addition, the Company believes that the use of protease inhibitors as a supportive therapy in various AIDs-related therapies has reduced domestic sales of NEUPOGEN(R) for off-label use in this setting. NEUPOGEN(R) is not approved or promoted for such use. Quarterly NEUPOGEN(R) sales volume in the United States is influenced by a number of factors including underlying demand and wholesaler inventory management practices. Wholesaler inventory reductions tend to reduce domestic NEUPOGEN(R) sales in the first quarter each year. In addition, the discretionary aspects of some cancer chemotherapy administration has had a slight seasonal effect on NEUPOGEN(R) sales. Cost containment pressures in the health care marketplace have contributed to the slowing of growth in domestic NEUPOGEN(R) usage over the past several years. These pressures are expected to continue to influence such growth for the foreseeable future. The growth of the colony stimulating factor ("CSF") market in the EU in which NEUPOGEN(R) competes has slowed, and is expected to continue to slow, principally due to cost controls resulting from government budget issues in EU countries. Additionally, the Company faces competition from another granulocyte CSF product. Although the Company's CSF market share in the EU has remained relatively constant over the last several quarters, the Company does not expect the competitive intensity to subside in the near future. EPOGEN(R) (Epoetin alfa) EPOGEN(R) sales were $294.9 million and $586.5 million for the three and six months ended June 30, 1997, respectively. These amounts represent increases of $30.7 million and $78.2 million or 12% and 15%, respectively, over the same periods last year. For the six months ended June 30, 1997, the increase was primarily due to continued increases in the U.S. dialysis patient population and, to a lesser extent, the administration of higher doses. Although sales in the three months ended June 30, 1997, did benefit from increases in the U.S. dialysis patient population, EPOGEN(R) sales in this period were adversely affected by reimbursement changes announced by the Health Care Finance Administration ("HCFA"). Prior to this change, Fiscal Intermediaries under contract to HCFA were authorized to pay reimbursement claims for patients whose hematocrits were above the FDA approved level of 36 percent with adequate medical justification. Under the new rules, medical justification will no longer be accepted for payment of claims above 36 percent, and reimbursement will be denied if the current month's hematocrit is 36 or above and the patient's hematocrit exceeds 36.5 percent on a 90-day "rolling average" basis. It has been and remains difficult to predict EPOGEN(R) usage during initial implementation of this new policy because individual patient hematocrit variability is high, the timing 19
and nature of dialysis center actions varies widely, and the twice postponed implementation date has lengthened the duration of the implementation period. Implementation, originally set for July 1, 1997, is now scheduled for September 1, 1997. The Company initially experienced an impact on EPOGEN(R) sales of withheld and lowered doses in the three months ended June 30, 1997, as some dialysis providers attempted to reduce hematocrits to avoid future claim denials. The Company anticipates that because patient hematocrits can vary significantly from month to month, physicians will withhold doses and administer reduced doses to patients to maintain hematocrits at a level which, in their judgment, is sufficiently low to avoid a claim denial. Amgen is aggressively providing information and guidance to dialysis providers on changes in their practices to both maximize patient outcomes to the greatest extent permitted by the new policy and minimize the potential that claims will be denied. It is not possible to predict which recommendations will be adopted by each dialysis center or when they will do so. Corporate partner revenues Corporate partner revenues decreased by $2 million, or 5%, and increased $3.6 million, or 6%, during the three and six months ended June 30, 1997, respectively, compared with the same periods last year. During the three months ended June 30, 1997 a $20 million milestone payment was received from Yamanouchi Pharmaceutical Co., Ltd. ("Yamanouchi") compared with a $15 million licensing payment earned from Yamanouchi during the second quarter of 1996. Despite this increase in funding from Yamanouchi, corporate partner revenues decreased during the three months ended June 30, 1997 compared with the same period last year primarily due to a reduction in funding from Kirin-Amgen, Inc. Cost of sales Cost of sales as a percentage of product sales was 13.6% and 13.5% for the three and six months ended June 30, 1997, respectively, compared to 13.2% and 13.6% for the same periods last year. In 1997, cost of sales as a percentage of product sales is expected to range from 13%-14% reflecting continuing efficiencies of the Puerto Rican operations. Research and development During the three and six months ended June 30, 1997, research and development expenses increased $21.8 million and $38.9 million, or 18% and 15%, respectively, compared with the same periods last year. These increases are primarily due to staff-related expenses for clinical and preclinical activities necessary to support ongoing product development activities. In 1997, annual research and development expenses are expected to increase at a rate exceeding the Company's product sales growth rate. This increase is planned for internal efforts on development of product candidates, for discovery, and for licensing efforts. Marketing and selling/General and administrative 20
Marketing and selling expenses increased $3.3 million and $3.8 million, or 4% and 3%, respectively, during the three and six months ended June 30, 1997 compared with the same periods last year. These increases were relatively small because higher staff-related costs and higher outside marketing expenses were substantially offset by lower European marketing expenses resulting from the favorable effects of foreign currency exchange rates, and lower expenses related to the Johnson & Johnson arbitration. General and administrative expenses increased $5.9 million and $11.1 million, or 16% and 14%, respectively, during the three and six months ended June 30, 1997 compared with the same periods last year These increases were primarily due to higher legal and staff-related expenses. In 1997, marketing and selling expenses combined with general and administrative expenses are expected to have an aggregate annual growth rate lower than the anticipated annual product sales growth rate due in part to the favorable impact of foreign currency exchange rates on European expenses and reduced expenses related to the Johnson & Johnson arbitration. Interest and other income Interest and other income increased $5.8 million and $2.7 million, or 48% and 9%, respectively, during the three and six months ended June 30, 1997 compared with the same periods last year. These increases are primarily due to gains on foreign currency denominated contracts and interest income from higher cash balances. These increases were partially offset by investment portfolio capital losses realized in the current year periods while capital gains were realized in the first quarter of 1996. Interest and other income is expected to fluctuate from period to period primarily due to changes in cash balances and interest rates. Income taxes The Company's effective tax rate for both the three and six months ended June 30, 1997 was 28.0% compared with 31.0% and 30.8%, respectively, for the same periods last year. These decreases in the tax rate resulted from a favorable ruling received in the third quarter of 1996 from the Puerto Rican government with respect to tollgate taxes applicable to earnings in Puerto Rico. In 1998, the Company expects the tax rate to increase to approximately 31%, due to a change in the U.S. federal tax law which limits the tax benefits related to manufacturing in Puerto Rico, the location of the Company's fill-and-finish facility. Foreign currency transactions The Company has a program to manage certain portions of its exposure to fluctuations in foreign currency exchange rates arising from international operations. The Company generally hedges the receivables and payables with foreign currency forward contracts, 21
which typically mature within six months. The Company uses foreign currency option and forward contracts which generally expire within 12 months to hedge certain anticipated future sales and expenses. At June 30, 1997, outstanding foreign currency option and forward contracts totaled $24.8 million and $77.4 million, respectively. Financial Outlook Worldwide NEUPOGEN(R) (Filgrastim) sales for 1997 are expected to grow at a rate lower than the 1996 growth rate. Future NEUPOGEN(R) sales increases are dependent primarily upon further penetration of existing markets, the timing and nature of additional indications for which the product may be approved and the effects of competitive products. Although not approved or promoted for use in Amgen's domestic or foreign markets, except for Australia, the Company believes that approximately 10% of its worldwide NEUPOGEN(R) sales are from off-label use as a supportive therapy in various AIDS- related treatments. Changes in AIDS therapies, including therapies that may be less myelosuppressive, are believed to have adversely affected and are expected to continue to adversely affect such sales. NEUPOGEN(R) usage is expected to continue to be affected by cost containment pressures on health care providers worldwide. In addition, international NEUPOGEN(R) sales will continue to be subject to changes in foreign currency exchange rates and government budgets. The Company believes that the EPOGEN(R) (Epoetin alfa) year- over-year sales growth rate for the second half of 1997 will be less than the 15% growth rate reported in the first half of this year. The Company also anticipates that increases in the U.S. dialysis patient population, and, to a lesser extent, dosing, will continue to drive EPOGEN(R) sales in future years. The Company anticipates that the total product sales growth rate in 1997 will be somewhat less than double digits. Earnings are expected to grow at a double digit rate in 1997, however, Amgen has advised analysts that it is no longer comfortable with the current range of their estimates of earnings per share. Estimates of future product sales and earnings, however, are necessarily speculative in nature and are difficult to predict with accuracy. Except for the historical information contained herein, the matters discussed herein are by their nature forward-looking. For reasons stated, or for various unanticipated reasons, actual results may differ materially. Amgen operates in a rapidly changing environment that involves a number of risks, some of which are beyond the Company's control. Future operating results and matters which may affect the Company's stock price may be affected by a number of factors, certain of which are discussed elsewhere herein and are discussed in the sections appearing under the heading "Management's Discussion and Analysis of Financial Condition and Results of Operations--Factors That May Affect Future Results" in the Company's Annual Report on Form 10-K for the year ended December 31, 1996, which sections are incorporated herein by reference and filed as an exhibit hereto. 22
Legal Matters The Company is engaged in arbitration proceedings with one of its licensees and various other legal proceedings. For a discussion of these matters, see Note 4 to the Condensed Consolidated Financial Statements. PART II - OTHER INFORMATION Item 1. Legal Proceedings The Company is engaged in arbitration proceedings with one of its licensees. For a complete discussion of these matters see Note 4 to the Condensed Consolidated Financial Statements - "Contingencies - Johnson & Johnson arbitrations". Other legal proceedings are also reported in Note 4 to the Condensed Consolidated Financial Statements and in the Company's Form 10-K for the year ended December 31, 1996, with material developments since that report described below. While it is not possible to predict accurately or to determine the eventual outcome of these matters, the Company believes that the outcome of these legal proceedings will not have a material adverse effect on the financial statements of the Company. False Claims Act matter As previously reported, Amgen was named as a defendant in a civil lawsuit initiated by a former employee of Amgen in the United States District Court for the Eastern District of Pennsylvania. This suit, United States ex rel. Eric Zwick v. Amgen Inc., et al., was filed under the qui tam provisions of the Federal False Claims Act. On June 11, 1997, after a full review of the allegations, the United States Department of Justice filed a Notice of Election to Decline Intervention in the lawsuit. In addition, on June 28, 1997, the Court granted the former employee's motion to dismiss the action without prejudice. Synergen ANTRIL(TM) litigation On June 13, 1997, the parties in the matter Susquehanna Investment Group, et al. v. Amgen Boulder, Inc., et al., agreed to a settlement in that matter in which Amgen Boulder, Inc. agreed to pay $1 million in exchange for dismissal of the suit. On July 23, 1997, the lawsuit was dismissed with prejudice. NESP Matter On June 5, 1997, Ortho Biotech, Inc. ("Ortho Biotech"), a Johnson & Johnson affiliate, filed a demand for arbitration against Kirin-Amgen, Inc. ("Kirin-Amgen"), before the American Arbitration Association ("AAA"). The demand alleges that Amgen's novel erythropoiesis stimulating protein ("NESP") is covered by a license granted by Kirin-Amgen to Ortho Pharmaceutical Corporation in 1985 for the development, manufacture and sale of Epoetin alfa in certain territories outside the United States, Japan and China. In 1996 Kirin-Amgen acquired exclusive worldwide rights in NESP from Amgen. 23
Kirin-Amgen, in turn, transferred certain rights in NESP to Kirin and certain rights to Amgen. Ortho Biotech alleges that Ortho Pharmaceutical's 1985 license agreement with Kirin-Amgen effectively grants Ortho Biotech the same right to develop, manufacture and sell NESP as Kirin-Amgen previously granted to Ortho Pharmaceutical in 1985 for the development, manufacture and sale of Epoetin alfa. On June 20, 1997 Kirin-Amgen initiated suit in the Circuit Court of Cook County, Illinois seeking a judicial determination of Ortho Biotech's standing to seek arbitration of claims under Kirin-Amgen's 1985 license agreement with Ortho Pharmaceutical. At the same time, Kirin-Amgen filed a motion with AAA to dismiss or stay the arbitration pending judicial resolution of Ortho Biotech's standing to arbitrate claims under Kirin-Amgen's license agreement with Ortho Pharmaceutical. Transkaryotic Therapies and Hoechst litigation On April 15, 1997, Amgen filed suit in the United States District Court in Boston Massachusetts against Transkaryotic Therapies Inc. ("TKT") and Hoechst Marion Roussel alleging infringement of several U.S. patents owned by Amgen that claim an erythropoietin product and processes for making erythropoietin. The suit seeks an injunction preventing the defendants from making, importing, using or selling erythropoietin in the U.S. On July 9, 1997, the Court denied TKT's motion to dismiss the lawsuit on the pleadings. Biogen litigation 24
On March 10, 1995, Biogen Inc. ("Biogen"), filed suit in the United States District Court for the District of Massachusetts alleging infringement by the Company of certain claims of U.S. Patent 4,874,702 (the "`702 Patent"), relating to vectors for expressing cloned genes. Biogen alleges that Amgen has infringed its patent by manufacturing and selling NEUPOGEN(R). On March 28, 1995, Biogen filed an amended complaint further alleging that the Company is also infringing the claims of two additional patents allegedly assigned to Biogen, U.S. Patent 5,401,642 (the "`642 Patent") and U.S. Patent No. 5,401,658 (the "`658 Patent"), relating to vectors, methods for making vectors and expressing closed genes. The amended complaint seeks injunctive relief, unspecified compensatory damages and treble damages. On April 24, 1995, the Company answered Biogen's amended complaint, denying its material allegations and pleading counterclaims for declaratory judgment of non-infringement, patent invalidity and unenforceability. On January 19, 1996, the Court decided, upon Biogen's motion to dismiss certain of Amgen's counterclaims, that it will exert jurisdiction over claims 9 and 17 of the `702 Patent, and dismissed all claims and counterclaims relating to any other claims of the `702 Patent. Amgen moved (the "Summary Adjudication Motion") for summary judgment of invalidity of claim 9 of the `702 Patent. On July 7, 1997, the Company's Summary Adjudication Motion was denied. This denial is not dispositive of the case, and the effect of the ruling may be to reserve certain issues for trial. Discovery is substantially complete. No trial date has been set. In a separate matter, on July 30, 1997, Biogen filed a complaint in the United States District Court for the District of Massachusetts in Boston alleging that Amgen infringes claims 9 and 17 of the `702 Patent, and the `642 Patent and `658 Patent by making and using the claimed subject matter in the United States in the manufacture of INFERGEN(R), the Company's consensus interferon product. As of July 31, 1997, Amgen had not been served with the complaint. Consensus interferon litigation On December 3, 1996, Schering Corporation filed suit in the U.S. District Court for the District of Delaware (the "Delaware Court") against the Company alleging infringement of U.S. Patent No. 4,530,901 (the "`901 Patent") by the manufacture and use of the Company's Consensus Interferon product. The complaint seeks unspecified damages and injunctive relief. The Company filed a motion to dismiss (the "Motion to Dismiss") the action on January 24, 1997. On January 22, 1997, the Company filed an action for declaratory relief in the United States District Court for the Central District of California in Los Angeles (the "California Court") naming Biogen Inc. and Schering Corporation as parties. The action seeks a declaration that the `901 Patent is not infringed by the Company's use of INFERGEN(R) and/or that the `901 Patent is invalid. By agreement between the parties, the Motion to Dismiss was withdrawn and a motion to transfer the case to California was filed on March 10, 1997. On June 24, 1997, the Delaware Court denied Amgen's motion to transfer and the case is now proceeding in Delaware. Pursuant to an agreement between the parties, Amgen 25
withdrew its complaint filed in California. Biogen has been added as a plaintiff in the Delaware action. FoxMeyer Health Corporation On January 10, 1997, FoxMeyer Health Corporation, now known as Avatex Corporation ("Avatex"), filed suit (the "FoxMeyer Lawsuit") in the District Court of Dallas County, Dallas, Texas, alleging that defendant McKesson Corporation ("McKesson") defrauded Avatex, misused confidential information received from Avatex about subsidiaries of Avatex (FoxMeyer Corporation and FoxMeyer Drug Corporation, collectively the "FoxMeyer Subsidiaries"), and attempted to monopolize the market for pharmaceutical and health care product distribution by attempting to injure or destroy the FoxMeyer Subsidiaries. The Company is named as one of twelve "Manufacturer Defendants" alleged to have conspired with McKesson Corporation in doing, among other things, the above and (i) inducing Avatex to refrain from seeking other suitable purchasers for the FoxMeyer Subsidiaries and (ii) causing Avatex to believe that McKesson was serious about purchasing Avatex's assets at fair value, when, in fact, McKesson was not. The Manufacturer Defendants and McKesson are also alleged to have intentionally and tortiously interfered with a number of business expectancies and opportunities. The complaint seeks from the Manufacturer Defendants and McKesson compensatory damages of at least $400 million and punitive damages in an unspecified amount, as well as Avatex's costs and attorney's fees. On January 31, 1997, the Company filed an answer denying Avatex's allegations. On February 4, 1997, a Notice of Removal was filed in the Federal District Court for Dallas, Texas (the "District Court"), which was referred by the District Court to the Federal Bankruptcy Court in Dallas, Texas (the "Texas Bankruptcy Court"). Subsequently, on February 7, 1997, a Motion to Transfer Venue was filed in the Texas Bankruptcy Court requesting that this matter be transferred to the Federal Bankruptcy Court in Delaware (the "Delaware Bankruptcy Court"), where the FoxMeyer Subsidiaries' Chapter 7 bankruptcy action is pending. The Company is a creditor in such bankruptcy proceeding. Avatex had moved to remand the case to state court. On March 18, 1997, the Manufacturer Defendants filed in the Delaware Bankruptcy Court a Motion to Intervene in the creditors' committee (the "Chapter 11 Committee") action that asserted that the Delaware Bankruptcy Court should enjoin the FoxMeyer Lawsuit. Also on March 18, 1997, the Delaware Bankruptcy Court converted the FoxMeyer Subsidiaries' Chapter 11 bankruptcy action to a liquidation proceeding under Chapter 7. The order converting the FoxMeyer Subsidiaries' bankruptcy to a Chapter 7 proceeding also stayed all adversary proceedings and other proceedings filed in the bankruptcy until a permanent trustee was elected. As of August 1, 1997, although the issues are fully briefed, no ruling has been made by the Dallas Bankruptcy Court with respect to either the Motion to Transfer Venue to the Delaware Bankruptcy Court or the Avatex Motion to Remand to state court. The trustee has moved to intervene as plaintiff in the Dallas Bankruptcy Court action, has filed a memorandum supporting transfer and has also filed a memorandum opposing remand or abstention. McKesson has intervened in the Delaware Bankruptcy Court action to enjoin the Avatex lawsuit and has moved for partial summary 26
judgment in that proceeding, asserting that Avatex is not the owner of the alleged causes of action. The Manufacturer Defendants have also intervened in that Delaware Bankruptcy Court action and have joined in McKesson's summary judgment motion. The trustee has substituted for the Chapter 11 Committee as the plaintiff in that action and has also filed its motion for partial summary judgment also asserting that Avatex does not own the causes of action. Avatex has moved to file its response to McKesson's motion for partial summary judgment under seal by reason of various deposition materials originally taken pursuant to a confidentiality order which materials are being utilized in connection with the partial summary judgment. McKesson has objected. Avatex has filed its answer and affirmative defenses to the McKesson complaint for injunction. To date, no discovery has occurred in either the Dallas Bankruptcy Court adversary proceedings or the Delaware Bankruptcy Court adversary proceeding for injunction. There are no pleadings yet on file by either the trustee, McKesson or the Manufacturer Defendants concerning the issue whether McKesson owns the alleged causes of action rather than the Chapter 7 trustee. Item 4. Submission of Matters to a Vote of Security Holders (a) The Company held its Annual Meeting of Stockholders on May 8, 1997. (b) Omitted pursuant to Instruction 3 to Item 4 of Form 10-Q. (c) The two matters voted upon at the meeting were to elect two directors to hold office until the Annual Meeting of Stockholders in the year 2000 and to ratify the selection of Ernst & Young LLP as the independent auditors of the Company for the year ending December 31, 1997. (i) The following votes were cast for or were withheld with respect to each of the nominees for director: Mr. Gordon M. Binder: 223,424,399 votes for and 1,923,447 votes withheld; and Mr. Franklin P. Johnson, Jr.: 223,431,735 votes for and 1,916,111 votes withheld. All nominees were declared to have been elected as directors to hold office until the Annual Meeting of Stockholders in the year 2000. No abstentions or broker non-votes were cast for the election of directors. (ii) With respect to the proposal to ratify the selection of Ernst & Young LLP as the Company's independent auditors, 224,423,943 votes were cast for the proposal, 344,215 votes were cast against the proposal and 579,678 votes abstained. No broker non-votes were cast in connection with the proposal. The selection of Ernst & Young LLP as the Company's independent auditors for the year ending December 31, 1997 was declared to have been ratified. 27
(d) Not applicable. Item 6. Exhibits and Reports on Form 8-K (a) Reference is made to the Index to Exhibits included herein. (b) Reports on Form 8-K The Company filed two Current Reports on Form 8-K during the three months ended June 30, 1997. The report filed on April 8, 1997 reported under Item 5 that the Company entered into an underwriting agreement pursuant to the sale of its debt securities and reported under Item 7 the list of related exhibits. The report filed on June 13, 1997 reported under Item 5 an update to certain litigation. 28
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Amgen Inc. (Registrant) Date: 8/11/97 By:/s/ Robert S. Attiyeh - ------------------ --------------------------------- Robert S. Attiyeh Senior Vice President, Finance and Corporate Development, and Chief Financial Officer Date: 8/11/97 By:/s/ Kathryn E. Falberg - ------------------ --------------------------------- Kathryn E. Falberg Vice President, Corporate Controller and Chief Accounting Officer 29
AMGEN INC. INDEX TO EXHIBITS Exhibit No. Description 3.1 Restated Certificate of Incorporation as amended. (26) *3.2 Amended and Restated Bylaws. 4.1 Indenture dated January 1, 1992 between the Company and Citibank N.A., as trustee. (11) 4.2 Forms of Commercial Paper Master Note Certificates. (14) 4.3 First Supplement to Indenture, dated February 26, 1997 between the Company and Citibank N.A., as trustee. (23) 4.4 Officer's Certificate pursuant to Sections 2.1 and 2.3 of the Indenture, as supplemented, establishing a series of securities "8-1/8% Debentures due April 1, 2097." (25) 4.5 8-1/8% Debentures due April 1, 2097. (25) 4.6 Form of stock certificate for the common stock, par value $.0001 of the Company. (26) 10.1 Company's Amended and Restated 1991 Equity Incentive Plan. (24) 10.2 Company's Amended and Restated 1984 Stock Option Plan. (21) 10.3 Shareholder's Agreement of Kirin-Amgen, Inc., dated May 11, 1984, between the Company and Kirin Brewery Company, Limited (with certain confidential information deleted therefrom). (1) 10.4 Amendment Nos. 1, 2, and 3, dated March 19, 1985, July 29, 1985 and December 19, 1985, respectively, to the Shareholder's Agreement of Kirin-Amgen, Inc., dated May 11, 1984 (with certain confidential information deleted therefrom). (3) 10.5 Product License Agreement, dated September 30, 1985, and Technology License Agreement, dated, September 30, 1985 between the Company and Ortho Pharmaceutical Corporation (with certain confidential information deleted therefrom). (2) 10.6 Product License Agreement, dated September 30, 1985, and Technology License Agreement, dated September 30, 1985 between Kirin-Amgen, Inc. and Ortho Pharmaceutical Corporation (with certain confidential information deleted therefrom). (3) 10.7 Company's Amended and Restated Employee Stock Purchase Plan. (21) 10.8 Research, Development Technology Disclosure and License Agreement PPO, dated January 20, 1986, by and between the Company and Kirin Brewery Co., Ltd. (4) 10.9 Amendment Nos. 4 and 5, dated October 16, 1986 (effective July 1, 1986) and December 6, 1986 (effective July 1, 1986), respectively, to the Shareholders Agreement of Kirin-Amgen, Inc. dated May 11, 1984 (with certain confidential information deleted therefrom). (5) 30
10.10 Assignment and License Agreement, dated October 16, 1986, between the Company and Kirin-Amgen, Inc. (with certain confidential information deleted therefrom). (5) 10.11 G-CSF European License Agreement, dated December 30, 1986, between Kirin-Amgen, Inc. and the Company (with certain confidential information deleted therefrom). (5) 10.12 Research and Development Technology Disclosure and License Agreement: GM-CSF, dated March 31, 1987, between Kirin Brewery Company, Limited and the Company (with certain confidential information deleted therefrom). (5) 10.13 Company's Amended and Restated 1987 Directors' Stock Option Plan. (24) 10.14 Company's Amended and Restated 1988 Stock Option Plan. (21) 10.15 Company's Amended and Restated Retirement and Savings Plan. (21) 10.16 Amendment, dated June 30, 1988, to Research, Development, Technology Disclosure and License Agreement: GM-CSF dated March 31, 1987, between Kirin Brewery Company, Limited and the Company. (6) 10.17 Agreement on G-CSF in the EU, dated September 26, 1988, between Amgen Inc. and F. Hoffmann-La Roche & Co. Limited Company (with certain confidential information deleted therefrom). (8) 10.18 Supplementary Agreement to Agreement dated January 4, 1989 to Agreement on G-CSF in the EU, dated September 26, 1988, between the Company and F. Hoffmann-La Roche & Co. Limited Company, (with certain confidential information deleted therefrom). (8) 10.19 Agreement on G-CSF in Certain European Countries, dated January 1, 1989, between Amgen Inc. and F. Hoffmann-La Roche & Co. Limited Company (with certain confidential information deleted therefrom). (8) 10.20 Rights Agreement, dated January 24, 1989, between Amgen Inc. and American Stock Transfer and Trust Company, Rights Agent. (7) 10.21 First Amendment to Rights Agreement, dated January 22, 1991, between Amgen Inc. and American Stock Transfer and Trust Company, Rights Agent. (9) 10.22 Second Amendment to Rights Agreement, dated April 2, 1991, between Amgen Inc. and American Stock Transfer and Trust Company, Rights Agent. (10) 10.23 Agency Agreement, dated November 21, 1991, between Amgen Manufacturing, Inc. and Citicorp Financial Services Corporation. (12) 10.24 Agency Agreement, dated May 21, 1992, between Amgen Manufacturing, Inc. and Citicorp Financial Services Corporation. (12) 10.25 Guaranty, dated July 29, 1992, by the Company in favor of Merck Sharp & Dohme Quimica de Puerto Rico, Inc. (13) 10.26 936 Promissory Note No. 01, dated December 11, 1991, issued by Amgen Manufacturing, Inc. (12) 10.27 936 Promissory Note No. 02, dated December 11, 1991, issued by Amgen Manufacturing, Inc. (12) 10.28 936 Promissory Note No. 001, dated July 29, 1992, issued by Amgen Manufacturing, Inc. (12) 31
10.29 936 Promissory Note No. 002, dated July 29, 1992, issued by Amgen Manufacturing, Inc. (12) 10.30 Guaranty, dated November 21, 1991, by the Company in favor of Citicorp Financial Services Corporation. (12) 10.31 Partnership Purchase Agreement, dated March 12, 1993, between the Company, Amgen Clinical Partners, L.P., Amgen Development Corporation, the Class A limited partners and the Class B limited partner. (13) 10.32 Amgen Supplemental Retirement Plan dated June 1, 1993. (15) 10.33 Promissory Note of Mr. Kevin W. Sharer, dated June 4, 1993. (15) 10.34 Promissory Note of Mr. Larry A. May, dated February 24, 1993. (16) 10.35 Amgen Performance Based Management Incentive Plan. (24) 10.36 Agreement and Plan of Merger, dated as of November 17, 1994, among Amgen Inc., Amgen Acquisition Subsidiary, Inc. and Synergen, Inc. (17) 10.37 Third Amendment to Rights Agreement, dated as of February 21, 1995, between Amgen Inc. and American Stock Transfer Trust and Trust Company (18) 10.38 Credit Agreement, dated as of June 23, 1995, among Amgen Inc., the Borrowing Subsidiaries named therein, the Banks named therein, Swiss Bank Corporation and ABN AMRO Bank N.V., as Issuing Banks, and Swiss Bank Corporation, as Administrative Agent. (19) 10.39 Promissory Note of Mr. George A. Vandeman, dated December 15, 1995. (20) 10.40 Promissory Note of Mr. George A. Vandeman, dated December 15, 1995. (20) 10.41 Promissory Note of Mr. Stan Benson, dated March 19, 1996. (20) 10.42 Amendment No. 1 to the Company's Amended and Restated Retirement and Savings Plan. (21) 10.43 Amendment Number 5 to the Company's Amended and Restated Retirement and Savings Plan dated January 1, 1993. (24) 10.44 Amendment Number 2 to the Company's Amended and Restated Retirement and Savings Plan dated April 1, 1996. (24) 10.45 First Amendment to Credit Agreement, dated as of December 12, 1996, among Amgen Inc., the Borrowing Subsidiaries named therein, and Swiss Bank Corporation as Administrative Agent. (24) 10.46 Fourth Amendment to Rights Agreement, dated February 18, 1997 between Amgen Inc. and American Stock Transfer and Trust Company, Rights Agent. (22) 10.47 Preferred Share Rights Agreement, dated February 18, 1997, between Amgen Inc. and American Stock Transfer and Trust Company, Rights Agent. (22) 10.48 Consulting Agreement, dated November 15, 1996, between the Company and Daniel Vapnek. (24) 10.49 Agreement, dated May 30, 1995, between the Company and George A. Vandeman. (24) *10.50 First Amendment, effective January 1, 1998, to the Company's Amended and Restated Employee Stock Purchase Plan. 32
*10.51 Third Amendment, effective January 1, 1997, to the Company's Amended and Restated Retirement and Savings Plan dated April 1, 1996. *10.52 Heads of Agreement dated April 10, 1997, between the Company and Kirin Amgen, Inc., on the one hand, and F. Hoffmann-La Roche Ltd., on the other hand (with certain confidential information deleted therefrom). *11 Computation of per share earnings. *27 Financial Data Schedule. *99 Sections appearing under the heading "Management's Discussion and Analysis of Financial Condition and Results of Operations-Factors That May Affect Future Results" in the Company's Annual Report on Form 10-K for the year ended December 31, 1996. - ---------------- * Filed herewith. (1) Filed as an exhibit to the Annual Report on Form 10-K for the year ended March 31, 1984 on June 26, 1984 and incorporated herein by reference. (2) Filed as an exhibit to Quarterly Report on Form 10-Q for the quarter ended September 30, 1985 on November 14, 1985 and incorporated herein by reference. (3) Filed as an exhibit to Quarterly Report on Form 10-Q for the quarter ended December 31, 1985 on February 3, 1986 and incorporated herein by reference. (4) Filed as an exhibit to Amendment No. 1 to Form S-1 Registration Statement (Registration No. 33-3069) on March 11, 1986 and incorporated herein by reference. (5) Filed as an exhibit to the Form 10-K Annual Report for the year ended March 31, 1987 on May 18, 1987 and incorporated herein by reference. (6) Filed as an exhibit to Form 8 amending the Quarterly Report on Form 10-Q for the quarter ended June 30, 1988 on August 25, 1988 and incorporated herein by reference. (7) Filed as an exhibit to the Form 8-K Current Report dated January 24, 1989 and incorporated herein by reference. (8) Filed as an exhibit to the Annual Report on Form 10-K for the year ended March 31, 1989 on June 28, 1989 and incorporated herein by reference. (9) Filed as an exhibit to the Form 8-K Current Report dated January 22, 1991 and incorporated herein by reference. (10) Filed as an exhibit to the Form 8-K Current Report dated April 12, 1991 and incorporated herein by reference. (11) Filed as an exhibit to Form S-3 Registration Statement dated December 19, 1991 and incorporated herein by reference. (12) Filed as an exhibit to the Annual Report on Form 10-K for the year ended December 31, 1992 on March 30, 1993 and incorporated herein by reference. (13) Filed as an exhibit to the Form 8-A dated March 31, 1993 and incorporated herein by reference. (14) Filed as an exhibit to the Form 10-Q for the quarter ended March 31, 1993 on May 17, 1993 and incorporated herein by reference. 33
(15) Filed as an exhibit to the Form 10-Q for the quarter ended September 30, 1993 on November 12, 1993 and incorporated herein by reference. (16) Filed as an exhibit to the Annual Report on Form 10-K for the year ended December 31, 1993 on March 25, 1994 and incorporated herein by reference. (17) Filed as an exhibit to the Form 8-K Current Report dated November 18, 1994 on December 2, 1994 and incorporated herein by reference. (18) Filed as an exhibit to the Form 8-K Current Report dated February 21, 1995 on March 7, 1995 and incorporated herein by reference. (19) Filed as an exhibit to the Form 10-Q for the quarter ended June 30, 1995 on August 11, 1995 and incorporated herein by reference. (20) Filed as an exhibit to the Annual Report on Form 10-K for the year ended December 31, 1995 on March 29, 1996 and incorporated herein by reference. (21) Filed as an exhibit to the Form 10-Q for the quarter ended September 30, 1996 on November 5, 1996 and incorporated herein by reference. (22) Filed as an exhibit to the Form 8-K Current Report dated February 18, 1997 on February 28, 1997 and incorporated herein by reference. (23) Filed as an exhibit to the Form 8-K Current Report dated March 14, 1997 on March 14, 1997 and incorporated herein by reference. (24) Filed as an exhibit to the Annual Report on Form 10-K for the year ended December 31, 1996 on March 24, 1997 and incorporated herein by reference. (25) Filed as an exhibit to the Form 8-K Current Report dated April 8, 1997 on April 8, 1997 and incorporated herein by reference. (26) Filed as an exhibit to the Form 10-Q for the quarter ended March 31, 1997 on May 13, 1997. 34